<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01908296</url>
  </required_header>
  <id_info>
    <org_study_id>6949-CL-0004</org_study_id>
    <nct_id>NCT01908296</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Effect of Multiple-dose of Fluvoxamine on the Plasma Concentration of Quetiapine (FK949E) in Healthy Male Volunteers</brief_title>
  <official_title>Phase I Study of FK949E - A Study of Drug-drug Interactions Between FK949E and Fluvoxamine in Healthy Male Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study was to assess the effect of multiple-dose fluvoxamine on the&#xD;
      pharmacokinetics of quetiapine (FK949E) in healthy adult male subjects. The safety of FK949E&#xD;
      in the population was also evaluated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax) of unchanged quetiapine</measure>
    <time_frame>For 48 hours after dosing.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC (area under the curve) of unchanged quetiapine</measure>
    <time_frame>For 48 hours after dosing.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>tmax of plasma concentration of unchanged quetiapine</measure>
    <time_frame>For 48 hours after dosing.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of plasma concentration of unchanged quetiapine</measure>
    <time_frame>For 48 hours after dosing.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax) of quetiapine metabolites</measure>
    <time_frame>For 48 hours after dosing.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC (area under the curve) of quetiapine metabolites</measure>
    <time_frame>For 48 hours after dosing.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax of plasma concentration of quetiapine metabolites</measure>
    <time_frame>For 48 hours after dosing.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of plasma concentration of quetiapine metabolites</measure>
    <time_frame>For 48 hours after dosing.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax) of unchanged fluvoxamine</measure>
    <time_frame>For 12 hours after dosing.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC (area under the curve) of unchanged fluvoxamine</measure>
    <time_frame>For 12 hours after dosing.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax of plasma concentration of unchanged fluvoxamine</measure>
    <time_frame>For 12 hours after dosing.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of plasma concentration of unchanged fluvoxamine</measure>
    <time_frame>For 12 hours after dosing.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by the incidence of adverse events, clinical tab tests, vital signs, 12-lead ECGs and physical exam</measure>
    <time_frame>Up to 20 Days.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <condition>Pharmacokinetics of Quetiapine</condition>
  <arm_group>
    <arm_group_label>FK949E group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>receiving FK949E with and without fluvoxamine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FK949E</intervention_name>
    <description>Oral</description>
    <arm_group_label>FK949E group</arm_group_label>
    <other_name>extended release formulation of quetiapine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluvoxamine</intervention_name>
    <description>Oral</description>
    <arm_group_label>FK949E group</arm_group_label>
    <other_name>Luvox®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body weight : ≥50.0 kg, &lt;80.0 kg&#xD;
&#xD;
          -  Body Mass Index : ≥17.6, &lt;26.4&#xD;
&#xD;
          -  Healthy, as judged by the investigator/subinvestigator based on the results of&#xD;
             physical examinations (subjective symptoms and objective findings) and all tests&#xD;
             obtained at screening and during the period from hospital admission to immediately&#xD;
             before study medication&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with the following history.&#xD;
&#xD;
               1. Hepatic disease (e.g. viral hepatitis, drug-induced liver injury).&#xD;
&#xD;
               2. Heart disease (e.g. congestive heart failure, angina pectoris, arrhythmia&#xD;
                  requiring&#xD;
&#xD;
                  treatment).&#xD;
&#xD;
               3. Respiratory disease (e.g. serious bronchial asthma, chronic bronchitis)&#xD;
&#xD;
               4. Gastrointestinal disease (e.g. serious peptic ulcer, gastroesophageal reflux&#xD;
                  esophagitis;&#xD;
&#xD;
                  diseases requiring several selections except for appendicitis)&#xD;
&#xD;
               5. Renal disease (e.g. acute renal failure, glomerulonephritis, interstitial&#xD;
                  nephritis).&#xD;
&#xD;
               6. Cerebrovascular disorder (e.g. cerebral infarction).&#xD;
&#xD;
               7. Malignant tumor.&#xD;
&#xD;
               8. Drug allergies. Allergic disorders (except for hay fever)&#xD;
&#xD;
               9. Drug dependence, alcohol dependence&#xD;
&#xD;
          -  Any disease (except dental caries)&#xD;
&#xD;
          -  A deviation from the normal reference range of blood pressure, pulse rate, body&#xD;
             temperature, or 12-lead ECG&#xD;
&#xD;
          -  A deviation of the following criteria for clinical laboratory tests.&#xD;
&#xD;
        The normal reference ranges specified at the study site will be used as the normal&#xD;
        reference ranges in the present study.&#xD;
&#xD;
          1. Hematology:&#xD;
&#xD;
               -  A deviation of ±20% from the upper or lower limit of the normal range&#xD;
&#xD;
          2. Blood biochemistry:&#xD;
&#xD;
               -  A deviation from the normal range for AST, ALT, creatinine (Cre), HbA1c or serum&#xD;
                  electrolytes.&#xD;
&#xD;
               -  A deviation of ±20% from the upper or lower limit of the normal range for other&#xD;
                  items than the above.&#xD;
&#xD;
               -  However, the lower limit of the normal range will not be established for items&#xD;
                  for which a deviation from the lower limit is not considered clinically&#xD;
                  significant[AST, ALT, total bilirubin (T-Bil), ALP, γ-GTP, LDH, CK, Cre, uric&#xD;
                  acid (UA), BUN, and total cholesterol (T-Cho)].&#xD;
&#xD;
          3. Urinalysis:&#xD;
&#xD;
               -  U-Glc and/or U-Pro results of (±) or worse&#xD;
&#xD;
               -  U-Uro results of (+) or worse&#xD;
&#xD;
          4. Urinary drug test:&#xD;
&#xD;
               -  A positive result for phencyclidine, benzodiazepine, cocaine, amphetamines,&#xD;
                  cannabis, opiates, barbiturates or tricyclic antidepressants&#xD;
&#xD;
          5. Immunological test:&#xD;
&#xD;
               -  A positive result for hepatitis B, hepatitis C, syphilis, or HIV&#xD;
&#xD;
                    -  History of treatment, including medication, within 14 days before the start&#xD;
                       of study drug administration&#xD;
&#xD;
                    -  Consumption of food or beverages containing St. John's Wort within 14 days&#xD;
                       before the start of study drug administration, or consumption of grapefruit&#xD;
&#xD;
                    -  Previous participation in a pre- or post-marketing clinical study of another&#xD;
                       prescription drug or a medical device within 120 days before the study&#xD;
&#xD;
                    -  History of administration of quetiapine&#xD;
&#xD;
                    -  History of administration of fluvoxamine&#xD;
&#xD;
                    -  Whole blood sampling of 400 mL or more within 90 days before the screening&#xD;
                       assessment, whole blood sampling of 200 mL or more within 30 days before the&#xD;
                       screening assessment, or blood component donation within 14 days before the&#xD;
                       screening assessment&#xD;
&#xD;
                    -  Routine excessive alcohol consumption (&quot;excessive alcohol&quot; is defined as an&#xD;
                       average of 45 g of alcohol per day [cf., a large bottle of beer containing&#xD;
                       25 g of alcohol, 180 mL of sake containing 22 g of alcohol])&#xD;
&#xD;
                    -  Subjects with a smoking habit (except those who quit smoking at least 90&#xD;
                       days before the screening assessment)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>44 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Kyushu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://www.astellasclinicalstudyresults.com/hcp/study.aspx?ID=173</url>
    <description>Link to results on Astellas Clinical Study Results website</description>
  </link>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>July 23, 2013</study_first_submitted>
  <study_first_submitted_qc>July 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2013</study_first_posted>
  <last_update_submitted>February 14, 2017</last_update_submitted>
  <last_update_submitted_qc>February 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>FK949E</keyword>
  <keyword>fluvoxamine</keyword>
  <keyword>Antipsychotic</keyword>
  <keyword>Quetiapine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Quetiapine Fumarate</mesh_term>
    <mesh_term>Fluvoxamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

